Basel, 23 April 2019 Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.1 About 15 to 20 percent of women diagnosed... Read more
APRIL 22, 2019 SHANGHAI and MINNEAPOLIS, April 22, 2019 /PRNewswire/ — Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the terms of the agreement, Elpiscience will have access to multiple antibodies from Bio-Techne’s extensive product portfolio for use in the development of preclinical, clinical, and commercial... Read more
Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC PD-L1 IHC 22C3 pharmDx Can Now Be Used to Identify a Broader Range of NSCLC Patients for First-line Treatment With KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., April 16, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has... Read more
Nijmegen, Netherlands, April 16, 2019 – At the opening event of the Netherlands X-omics Initiative, Bruker and the Translation Metabolic Laboratory (TML) at Radboud University Medical Center (UMC) today jointly announce the establishment of a Center of Excellence (CoE) for Translational Omics. Under the leadership of Professor Alain van Gool, the joint CoE will focus on... Read more
San Jose, Calif. – (April 16, 2019) – Thermo Fisher Scientific, the world leader in serving science, and NX Prenatal Inc., a recognized leader in the detection, monitoring and management of pregnancy-related complications using novel exosome-based methods, have entered into a collaboration to develop clinical mass spectrometry-based proteomics assays to monitor fetal health in utero and assess the risk... Read more
– Reference library expansion for broader species identification by MALDI Biotyper (MBT) – Increased speed for high-throughput projects by multi-threading MBT HT software (RUO) – Increased microbial ID from positive blood cultures with improved Sepsityper™ kit – Easier subtyping for hospital hygiene and infection control with improved IR Biotyper AMSTERDAM, April 15, 2019 /PRNewswire/ — At... Read more
First large-scale clinico-genomic MS study by leading healthcare system to advance research by building multi-dimensional datasets from a diverse population of more than 3,000 patients April 15, 2019 08:00 AM Eastern Daylight Time MOUNTAIN VIEW, Calif. & SACRAMENTO, Calif.–(BUSINESS WIRE)–DNAnexus, Inc., and the not-for-profit Sutter Health network today announced the first large-scale clinico-genomic multiple sclerosis (MS) research... Read more
Germantown, Maryland, and Hilden, Germany, April 12 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech,... Read more
Hilden, Germany; Germantown, Maryland; and Amsterdam, Netherlands, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON®-TB test for detection of latent tuberculosis (TB) infections has surpassed 60 million tests administered, having impacted the lives of millions of patients worldwide and supporting the global fight... Read more
Hilden, Germany, and Ann Arbor, Michigan, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion of the content menu for the NeuMoDx™ 96 and 288 Molecular Systems, as well as the commercial availability of the NeuMoDx 96 mid-throughput version of this family of fully... Read more